29-Oct-2026 08:22:45
CONCORDBIOGeneral news
JEFFERIES ON CONCORD BIOTECH ; HOLD | TP ₹1,360 (EARLIER ₹1,268)
• Target Upgrade: Jefferies raises target price to ₹1,360 from ₹1,268, maintaining Hold rating. • Q2 Revenue: UP 25% YoY, broadly in line with estimates. • Q2 EBITDA: UP 18% YoY, supported by revenue growth. • EBITDA Margins: DOWN 200 bps due to higher raw material costs and losses in new businesses. • Raw Material Costs: Rising input costs continue to pressure operating profitability. • FY27 Guidance: Management retains revenue growth guidance of over 20%. • Margin Outlook: Gradual margin recovery expected as cost pressures ease. • Impact: Mixed 🟡
CONCORD BIOTECH LIMITED